[Remote] Vice President, MRD Clinical Strategy at Tempus

Tennessee, United States

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Medical Doctorate degree
Minimum of 12 years of experience in the healthcare or biotechnology industry, with a focus on molecular diagnostics or oncology
Proven track record of leadership in MRD (Minimal Residual Disease) or related areas, including experience in assay development and clinical study design
Experience working with regulatory agencies and understanding of regulatory requirements for diagnostic products
Strong strategic thinking and problem-solving skills
Excellent communication and presentation skills
Demonstrated ability to build and maintain strategic partnerships and collaborations
Experience leading cross-functional teams and managing complex projects
Ability to influence and drive initiatives across diverse teams
Willingness to travel as needed
Strong commitment to advancing precision medicine and improving patient outcomes

Responsibilities

Act as Tempus’ senior representative and thought leader on MRD
Represent Tempus at scientific conferences, advisory boards, and industry forums
Build and maintain strategic partnerships with academic institutions, cooperative groups, and biopharma collaborators
Define and execute the enterprise MRD strategy aligned with Tempus priorities
Lead MRD assay development, clinical study design, validation, and regulatory readiness
Support business development and partnership opportunities to expand the MRD portfolio
Oversee cross-functional initiatives spanning R&D, clinical, medical affairs, and commercial teams
Engage with commercial stakeholders during external discussions

Skills

Tempus

AI-driven healthcare data analysis platform

About Tempus

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.

Chicago, IllinoisHeadquarters

2015Year Founded

$894.9MTotal Funding

IPOCompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Risks

Competition from partners like Genialis may lead to conflicts of interest.

Ambry Genetics acquisition could pose financial risks if synergies aren't realized.

Technical challenges may arise in integration with Flatiron's OncoEMR platform.

Differentiation

Tempus uses AI to analyze clinical and molecular data for precision medicine.

Their platform aids in personalized treatment decisions for cancer patients.

Tempus collaborates with biotech firms to enhance drug development using real-world data.

Upsides

Increased AI adoption in healthcare boosts Tempus' partnerships and collaborations.

Acquisition of Ambry Genetics expands Tempus' genetic testing capabilities.

Integration with Flatiron's OncoEMR enhances precision in cancer treatment plans.

Land your dream remote job 3x faster with AI

Try Jobo Free